Search results
Results from the WOW.Com Content Network
Bayer's executive board won a clear vote of confidence from shareholders on Tuesday, following a rebuke last year over the handling of lawsuits related to a weedkiller. Of the valid votes cast at ...
Bayer shareholder Union Investment on Monday came out in support of the drugmaker's chief executive serving out his full term after the CEO came under renewed pressure over the company's performance.
FRANKFURT (Reuters) -Bayer CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare and agriculture group, defying a ...
Bayer AG (English: / ˈ b aɪ. ər /, commonly pronounced / ˈ b eɪ ər /; [3] German:) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world.
The Bayer-Monsanto merger is widely considered to be one of the worst mergers in history, mostly due to the exposure to Roundup litigation. [109] [14] [15] [16] By 2023, Bayer's market value had declined by over 60% since its 2016 merger, leaving the company's overall worth at less than half of what it paid to acquire Monsanto. [109]
William Anderson (born August 23, 1966) is an American business executive who has been the chief executive officer (CEO) of Bayer AG since June 2023. [1] [2]Prior to his current role, Anderson was CEO of Genentech from 2017 to 2018, and later CEO of the Roche's Pharmaceuticals Division from 2019 to 2022.
A top 10 Bayer investor, who declined to be named, said Anderson would struggle to convince shareholders of the need for a cash call over internal restructuring and asset disposals.
Losses for Bayer investors reach tens of billions of Euros just two years after the acquisition. His position as CEO of Bayer was renewed in 2020 until 2024 before the general meeting of shareholders in 2021. [10] [11] [12] By 2023, Bayer investor DekaBank called for Baumann to be replaced ahead of his scheduled departure. [13]